These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18463999)

  • 21. Understanding Stimulant Use and Use Disorders in a New Era.
    Ciccarone D; Shoptaw S
    Med Clin North Am; 2022 Jan; 106(1):81-97. PubMed ID: 34823736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychopathology in methamphetamine-dependent adults 3 years after treatment.
    Glasner-Edwards S; Mooney LJ; Marinelli-Casey P; Hillhouse M; Ang A; Rawson RA;
    Drug Alcohol Rev; 2010 Jan; 29(1):12-20. PubMed ID: 20078677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors.
    Akindipe T; Wilson D; Stein DJ
    Metab Brain Dis; 2014 Jun; 29(2):351-7. PubMed ID: 24532047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between illicit amphetamine use and psychiatric symptom profiles in schizophrenia and affective psychoses.
    Voce A; McKetin R; Burns R; Castle D; Calabria B
    Psychiatry Res; 2018 Jul; 265():19-24. PubMed ID: 29680513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine.
    Harro J
    Int Rev Neurobiol; 2015; 120():179-204. PubMed ID: 26070758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment-seekers: meta-analytic findings across eight NIDA CTN trials.
    Hartzler B; Donovan DM; Huang Z
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):460-71. PubMed ID: 21854291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders.
    Temmingh HS; van den Brink W; Howells F; Sibeko G; Stein DJ
    J Dual Diagn; 2020; 16(2):208-217. PubMed ID: 31984872
    [No Abstract]   [Full Text] [Related]  

  • 29. Stimulant dependence and stimulant-associated psychosis: clinical characteristics and age of onset in a native American community sample.
    Gilder DA; Gizer IR; Lau P; Ehlers CL
    J Addict Med; 2014; 8(4):241-8. PubMed ID: 24755633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial.
    Nejtek VA; Avila M; Chen LA; Zielinski T; Djokovic M; Podawiltz A; Kaiser K; Bae S; Rush AJ
    J Clin Psychiatry; 2008 Aug; 69(8):1257-66. PubMed ID: 18681757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians.
    Rawls SM; Cavallo F; Capasso A; Ding Z; Raffa RB
    Eur J Pharmacol; 2008 Apr; 584(2-3):278-84. PubMed ID: 18342307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
    Siefried KJ; Acheson LS; Lintzeris N; Ezard N
    CNS Drugs; 2020 Apr; 34(4):337-365. PubMed ID: 32185696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prize-based contingency management does not increase gambling.
    Petry NM; Kolodner KB; Li R; Peirce JM; Roll JM; Stitzer ML; Hamilton JA
    Drug Alcohol Depend; 2006 Jul; 83(3):269-73. PubMed ID: 16377101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risks of psychosis in methamphetamine users: cross-sectional study in Thailand.
    Lamyai W; Pono K; Indrakamhaeng D; Saengsin A; Songhong N; Khuwuthyakorn P; Sribanditmongkol P; Junkuy A; Srisurapanont M
    BMJ Open; 2019 Oct; 9(10):e032711. PubMed ID: 31615802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychostimulant use and the brain.
    Lappin JM; Sara GE
    Addiction; 2019 Nov; 114(11):2065-2077. PubMed ID: 31321819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility and acceptability of approach bias modification during methamphetamine withdrawal and related methamphetamine use outcomes.
    Manning V; Garfield JBB; Mroz K; Campbell SC; Piercy H; Staiger PK; Lum JAG; Lubman DI; Verdejo-Garcia A
    J Subst Abuse Treat; 2019 Nov; 106():12-18. PubMed ID: 31540606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin conductance hypo-responding in recently abstinent cocaine dependent inpatients.
    Killeen TK; Brady KT
    Am J Addict; 2000; 9(2):154-62. PubMed ID: 10934577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report.
    Gillin JC; Pulvirenti L; Withers N; Golshan S; Koob G
    Biol Psychiatry; 1994 Jun; 35(11):843-9. PubMed ID: 8054406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Misuse of methamphetamine and prescription stimulants among youths and young adults in the community.
    Wu LT; Pilowsky DJ; Schlenger WE; Galvin DM
    Drug Alcohol Depend; 2007 Jul; 89(2-3):195-205. PubMed ID: 17257780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the invariance of the Stimulant Craving Questionnaire (STCQ) across cocaine and methamphetamine users.
    Northrup TF; Green C; Walker R; Greer TL; Trivedi MH
    Addict Behav; 2015 Mar; 42():144-7. PubMed ID: 25462663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.